Jun 2026 (Q2 FY26) — Aug 5, 2026
Agilon Health Q2 FY26 — Strong Performance and Raised Full-Year Guidance
Read the full callAgilon Health (AGL) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Agilon Health earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,495 | +7.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 0.8 | +9.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 18.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$88.45 +1.20% · +$1.05
Performance +323.2% YTD
YTD: $20.9 on 3 Jul 2026 → $88.45. High $96.11 (25 Aug 2026), low $12.19 (30 Jul 2026).
- Previous close
- $87.4
- 52-week range
- $12.19 – $96.11
Overview
- Symbol
- AGL
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Agilon Health earnings calls (AGL)
Financials
What the filings say
Net profit, year on year: +117% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,451 | 1,522 | 1,533 | 1,395 | 1,435 | 1,569 | 1,420 | 1,495 |
| Expenses | 1,584 | 1,631 | 1,555 | 1,511 | 1,567 | 1,763 | 1,416 | 1,483 |
| Operating profit | -134 | -108 | -22 | -116 | -131 | -194 | 4 | 12 |
| Operating margin | −9.2% | −7.1% | −1.4% | −8.3% | −9.2% | −12.3% | 0.3% | 0.8% |
| Other income | 16 | 8 | 9 | 8 | 9 | 41 | 16 | 15 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | — | — | 0 | 0 | — | — | 0 | 0 |
| Profit before tax | -117 | -105 | -2 | -104 | -111 | -188 | 30 | 18 |
| Tax rate | 0.5% | −1.7% | −11.6% | −0.1% | 0.3% | −0.7% | 0.1% | −2.1% |
| Net profit | -118 | -106 | 12 | -104 | -110 | -189 | 49 | 18 |
| EPS ($ per share) | — | — | 0.73 | -6.31 | — | — | 2.95 | 1.07 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | 2 | 4 | 4 | 4 | 4 | 0 |
| Reserves | — | -551 | -958 | -1,064 | -1,327 | -1,587 | -1,978 |
| Total liabilities | — | 422 | 495 | 657 | 1,080 | 1,263 | 1,145 |
| Fixed assets | — | 6 | 9 | 20 | 28 | 28 | 25 |
| Investments | — | — | 0 | 412 | — | — | — |
| Total assets | — | 446 | 1,586 | 1,697 | 1,741 | 1,734 | 1,271 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -104 | -53 | -148 | -131 | -156 | -58 | -106 |
| Cash from investing | -5 | 22 | -91 | -444 | -44 | 140 | 89 |
| Cash from financing | 176 | 25 | 1,154 | 28 | -193 | -3 | -3 |
| Net cash flow | — | — | — | — | -393 | 80 | -20 |
| Capital expenditure | -3 | -2 | -7 | -15 | -16 | -13 | -13 |
| Free cash flow | -107 | -55 | -155 | -146 | -172 | -71 | -119 |
Insider filings
40 filings between Nov 12, 2025 and Aug 16, 2026.
Open market
decisions to buy or sellPurchases
$352.0K
5 purchases by 4 insiders
Sales
None
No insider sold shares.
Some filings report no price, so the dollar figures above are a floor, not a total.
Compensation
not trading decisions- 14
- Award — granted as compensation
- 21
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Shaker Benjamin | $301.1K | — | Mar 9, 2026 |
| Wulf John William | $50.9K | — | Nov 12, 2025 |
| Venkatachaliah Girish | $0 | — | Mar 9, 2026 |
| Zamore Denise | $0 | — | Mar 9, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 16, 2026 | Gertsch Timothy Chief Accounting Officer | Tax withheld | 17 | $1.6K |
| Aug 1, 2026 | Zamore Denise Chief Legal Officer | Tax withheld | 37 | $3.4K |
| Jul 1, 2026 | Schwaneke Jeffrey A. Chief Financial Officer | Tax withheld | 2,311 | $258.2K |
| Jun 2, 2026 | MCKENZIE DIANA Director | Award | 2,133 | $0 |
| Jun 2, 2026 | Mansukani Sharad Director | Award | 2,133 | $0 |
| Jun 2, 2026 | Battaglia Silvana Director | Award | 2,133 | $0 |
| Jun 2, 2026 | McLoughlin Karen Director | Award | 2,133 | $0 |
| Jun 2, 2026 | WILLIAMS RONALD A Director | Award | 2,133 | $0 |
| Jun 2, 2026 | Wulf John William Director | Award | 2,133 | $0 |
| Jun 1, 2026 | Zamore Denise Chief Legal Officer | Tax withheld | 485 | $44.9K |
| May 24, 2026 | Gertsch Timothy Chief Accounting Officer | Tax withheld | 8 | $691 |
| May 7, 2026 | O'Rourke Timothy Patrick CEO & President | Award | 200,000 | $0 |
| May 7, 2026 | O'Rourke Timothy Patrick CEO & President | Award | 120,000 | $0 |
| Apr 15, 2026 | Zamore Denise Chief Legal Officer | Tax withheld | 220 | $5.9K |
| Apr 15, 2026 | Shaker Benjamin Chief Markets Officer | Tax withheld | 571 | $15.3K |
| Apr 15, 2026 | Gertsch Timothy Chief Accounting Officer | Tax withheld | 122 | $3.3K |
| Apr 15, 2026 | Venkatachaliah Girish Chief Technology Officer | Tax withheld | 330 | $8.9K |
| Apr 14, 2026 | Gertsch Timothy Chief Accounting Officer | Tax withheld | 25 | $567 |
| Apr 14, 2026 | Venkatachaliah Girish Chief Technology Officer | Tax withheld | 96 | $2.2K |
| Apr 14, 2026 | Zamore Denise Chief Legal Officer | Tax withheld | 20 | $454 |
| Apr 14, 2026 | Shaker Benjamin Chief Markets Officer | Tax withheld | 104 | $2.4K |
| Apr 1, 2026 | Venkatachaliah Girish Chief Technology Officer | Award | 28,000 | $0 |
| Apr 1, 2026 | Gertsch Timothy Chief Accounting Officer | Tax withheld | 266 | $2.6K |
| Apr 1, 2026 | Gertsch Timothy Chief Accounting Officer | Award | 10,000 | $0 |
| Apr 1, 2026 | Shaker Benjamin Chief Markets Officer | Tax withheld | 1,664 | $16.2K |
| Apr 1, 2026 | Schwaneke Jeffrey A. Chief Financial Officer | Tax withheld | 1,662 | $16.2K |
| Apr 1, 2026 | Schwaneke Jeffrey A. Chief Financial Officer | Award | 75,000 | $0 |
| Apr 1, 2026 | Shaker Benjamin Chief Markets Officer | Award | 70,000 | $0 |
| Apr 1, 2026 | Zamore Denise Chief Legal Officer | Tax withheld | 1,024 | $10.0K |
| Apr 1, 2026 | Zamore Denise Chief Legal Officer | Award | 50,000 | $0 |
| Apr 1, 2026 | Venkatachaliah Girish Chief Technology Officer | Tax withheld | 480 | $4.7K |
| Mar 9, 2026 | Zamore Denise Chief Legal Officer | Tax withheld | 2,056 | $1.2K |
| Mar 9, 2026 | Shaker Benjamin Chief Markets Officer | Purchase | 18,448 | — |
| Mar 9, 2026 | Shaker Benjamin Chief Markets Officer | Tax withheld | 6,348 | $3.8K |
| Mar 9, 2026 | Venkatachaliah Girish Chief Technology Officer | Purchase | 18,448 | — |
| Mar 9, 2026 | Venkatachaliah Girish Chief Technology Officer | Tax withheld | 6,477 | $3.9K |
| Mar 9, 2026 | Zamore Denise Chief Legal Officer | Purchase | 5,535 | — |
| Mar 2, 2026 | Shaker Benjamin Chief Markets Officer | Purchase | 500,000 | $301.1K |
| Jan 10, 2026 | Schwaneke Jeffrey A. Chief Financial Officer | Award | 600,000 | $0 |
| Nov 12, 2025 | Wulf John William Director | Purchase | 81,000 | $50.9K |
| Aug 16, 2025 | Gertsch Timothy Chief Accounting Officer | Tax withheld | 406 | $451 |
| Aug 1, 2025 | Zamore Denise Chief Legal Officer | Tax withheld | 915 | $1.6K |
| Jul 1, 2025 | Schwaneke Jeffrey A. Chief Financial Officer | Tax withheld | 46,099 | $109.7K |
| May 28, 2025 | Battaglia Silvana Director | Award | 78,724 | $0 |
| May 28, 2025 | Mansukani Sharad Director | Award | 78,724 | $0 |
| May 28, 2025 | McLoughlin Karen Director | Award | 78,724 | $0 |
| May 28, 2025 | WILLIAMS RONALD A Director | Award | 78,724 | $0 |
| May 28, 2025 | Wulf John William Director | Award | 78,724 | $0 |
| May 28, 2025 | MCKENZIE DIANA Director | Award | 78,724 | $0 |
| May 28, 2025 | Schwaneke Jeffrey A. Chief Financial Officer | Tax withheld | 9,331 | $21.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for agilon health, inc.
Free account. Everything above stays public.
Write why you follow agilon health, inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading